Benzinga | Nov 3, 2020 07:26AM EST

Cowen & Co. Initiates Coverage On Spruce Biosciences with Outperform Rating, Announces Price Target of $44

Cowen & Co. initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Outperform rating and announces Price Target of $44.